APIE Therapeutics Appoints Ashwin Datt Chief Executive Officer
11. Juli 2023 08:00 ET
|
APIE Therapeutics
Research Triangle Park, NC, July 11, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin...
APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
21. März 2023 08:00 ET
|
APIE Therapeutics
Cary, NC, March 21, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced...
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
30. August 2022 08:00 ET
|
APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
02. August 2022 10:15 ET
|
APIE Therapeutics
Cary, NC, Aug. 02, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ),...
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
12. Januar 2022 07:30 ET
|
APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
18. März 2021 08:11 ET
|
APIE Therapeutics
Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...